June 23, 2025- Medtronic will present data at the American Diabetes Association (ADA) 85th Scientific Sessions in Chicago, highlighting improved glycemic outcomes for individuals with insulin-intensive type 2 diabetes on the MiniMed™ 780G system under investigational use. Participants in a clinical trial achieved an average 8.6% increase in Time in Range (TIR), reaching 84.9%, well above the ADA goal of 70%, and a HbA1C reduction from 7.7% to 6.9%, meeting ADA targets for diabetes management.
Separately, results from the Medtronic LENNY trial were published in The Lancet Diabetes & Endocrinology. This multi-center, randomized controlled, crossover trial evaluated the MiniMed™ 780G system in young children (ages 2-6 years) with type 1 diabetes in a home setting. Results showed those using the MiniMed™ 780G system with SmartGuard™ achieved a 0.6% lower HbA1C and 9.9% higher Time in Range when compared to a baseline therapy of manual mode or hybrid closed loop without autocorrections. Parents and caregivers also reported improved sleep quality and lower fear of hypoglycemia when the system was used in auto mode (with SmartGuard™) compared to manual mode.